title: N-desalkylquetiapine activates ERK1/2 to induce GDNF release in C6 glioma cells: a putative cellular mechanism for quetiapine as antidepressant.
abstract: Quetiapine is an atypical antipsychotic which has been suggested to possess also antidepressant efficacy in the treatment of bipolar and unipolar depression. Recently, a link between the activation of the ERK/MAPK signalling pathway and the release of GDNF has been proposed as a specific feature of antidepressants. To obtain a first insight into the putative molecular mechanism of action of quetiapine, we examined its impact and that of its major metabolite norquetiapine on the activation of the ERK/MAPK signalling pathway in C6 glioma cells. Additionally, we investigated the induction of GDNF release as a possible physiological consequence of this activation. We found that norquetiapine, similarly to the antidepressant reboxetine, activated both ERK1 and ERK2 (pERK) with consequent enhanced release of GDNF; this release was dependent on pERK, as demonstrated by its reversibility after pre-treatment with a pharmacological pERK inhibitor. In contrast, quetiapine induced activation of ERK2 only. It also caused release of GDNF, but this release was independent of ERK activation. To test whether the simultaneous activation of ERK1 with ERK2 was critical for the observed pERK-dependent GDNF release, we specifically inactivated ERK1 mRNA via RNA interference. Our data show that indeed ERK1 plays an essential role, as GDNF release was hampered after Erk1 downregulation comparably to a pharmacological pERK inhibitor. Thus, activation of only ERK2 appears not to be sufficient for promoting GDNF release. Our results reveal the release of GDNF as a consequence of ERK/MAPK signalling activation by norquetiapine, which may contribute to the putative antidepressant properties of quetiapine. This article is part of a Special Issue entitled 'Anxiety and Depression'.
authors.affiliation: Max Planck Institute of Psychiatry, Munich, Germany. barbara@mpipsykl.mpg.de
authors.forename: Barbara
authors.initials: B
authors.lastname: Di Benedetto
authors.forename: Ralf
authors.initials: R
authors.lastname: Kühn
authors.forename: Caroline
authors.initials: C
authors.lastname: Nothdurfter
authors.forename: Theo
authors.initials: T
authors.lastname: Rein
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Wurst
authors.forename: Rainer
authors.initials: R
authors.lastname: Rupprecht
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D003987:Dibenzothiazepines / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation / Q000187:drug effects; D004797:Enzyme-Linked Immunosorbent Assay; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D051100:Glial Cell Line-Derived Neurotrophic Factor / Q000378:metabolism*; D005910:Glioma / Q000473:pathology; D045022:Lactate Dehydrogenases / Q000378:metabolism; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism; D011437:Propylamines / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D000069348:Quetiapine Fumarate; D012333:RNA, Messenger / Q000378:metabolism; D034741:RNA, Small Interfering / Q000378:metabolism; D051381:Rats; D014162:Transfection
chemical_list: D000928:Antidepressive Agents; D003987:Dibenzothiazepines; D051100:Glial Cell Line-Derived Neurotrophic Factor; D011437:Propylamines; D011725:Pyridines; D012333:RNA, Messenger; D034741:RNA, Small Interfering; C058964:CM 40534; D000069348:Quetiapine Fumarate; D045022:Lactate Dehydrogenases; D048052:Mitogen-Activated Protein Kinase 3; D020929:Mitogen-Activated Protein Kinase Kinases